Eastgate Biotech Company Description

Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products.

The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes.

It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil.

Eastgate Biotech Corp. has collaboration with Biotech Corp. to develop a vaccine against COVID-19. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014.

Eastgate Biotech Corp. was founded in 1999 and is based in Toronto, Canada.

Eastgate Biotech Corp.

Country	United States
Founded	1999
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	3
CEO	Rosella Perri

Contact Details

Address: 65 Harbour Square Toronto, Nevada M5J 2L4 Canada
Phone	647-692-0652
Website	EastGateBiotech.com

Stock Details

Ticker Symbol	ETBI
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US2772531008
SIC Code	2834

Key Executives

Name	Position
Rosella C. Perri	Chief Executive Officer, Secretary, Treasurer and Director
William D. Abajian	Vice Chairman, President and Chief Operating Officer
Dr. Joseph Schwarz Ph.D.	Chief Scientific Officer